Oventus Medical (ASX: OVN) Share Price and News





  (20 mins delayed)

52 Week Range


1 Year Return


Oventus Medical Chart and Price Data

Fundamentals Data provided by Morningstar.

Share Price

Day Change

52 Week Range


Yesterday's Close

Today's Open

Days Range



Avg. Volume (1 month)


as at 24 Feb 3:44pm

  • Oventus Medical (ASX: OVN)
    Latest News

    hand on touch screen lit up by a share price chart moving higher
    Share Market News

    Why the Oventus Medical (ASX:OVN) share price is up 7%

    The Oventus Medical (ASX:OVN) share price rose today following the release of the company's half-year results for FY21. Here's a…

    Read more »

    OVN ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size

    About Oventus Medical

    Oventus Medical Ltd. develops oral appliances for the treatment of obstructive sleep disordered and snoring. It offers an oral device under the O2Vent brand. The O2Vent unique design directs the air flow through to the back of the throat, alleviating multiple sites of obstruction including the nose, soft palate and tongue The company was founded by Christopher Patrick Hart in 2012 and is headquartered in Indooroopilly, Australia.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Ms Sue(Susan) MacLeman Non-Executive DirectorNon-Executive Chairman Nov 2015
    Ms MacLeman has more than 30 years of experience as a pharmaceutical, biotechnology and medical technology executive having held senior roles in corporate, medical, commercial and business development. Sue has also served as CEO and Board member of several ASX and NASDAQ listed companies in the pharmaceutical sector. Sue is also appointed to several academic and government advisory committees including CSIRO Health and Biosecurity Advisory Committee, Prime Ministers Digital Expert Advisory Committee, DMTC Medical Countermeasures and various COVID19 taskforces. She is a member of the Risk Management committee.
    Mr Jason (Jake) Nunn Non-Executive Director Feb 2020
    Mr Nunn has more than 25 years of experience in the life science industry as an investor, independent director, research analyst and investment banker. Jason is currently a venture advisor at New Enterprise Associates (NEA), where he was a partner from 2006 to 2018. Jason is a Director of Addex Therapeutics (SIX,Nasdaq: ADXN), Regulus Therapeutics (Nasdaq: RGLS) and Trevena, Inc. (Nasdaq: TRVN). He was a previous Director of several companies in the pharmaceutical sector including Dermira Inc. (acquired by Eli Lilly) and Hyperion Therapeutics (acquired by Horizon Pharma plc), and a board observer at Vertiflex, Inc. (acquired by Boston Scientific). Prior to NEA, Jason was a Partner specializing in life sciences investing at MPM Capital. Previously, he was a healthcare research analyst and portfolio manager at Franklin Templeton Investments and an investment banker with Alex. Brown & Sons. He is a member of the Risk Management Committee.
    Mr Paul Molloy Non-Executive Director Dec 2019
    Mr Molloy has twentyfive years of experience leading a range of public, private and venture capital funded healthcare companies. He is currently President and CEO of ClearFlow Inc., a US-based medical device company. Before joining ClearFlow, Paul was CEO at VasoNova Inc.- a Silicon Valley-based, venture funded vascular navigation company which was acquired by Teleflex Inc. (NYSE, TFX), in January 2011. Following the acquisition, he was appointed President of Teleflex' division - ARROW Vascular - having full P&L responsibilities for direct sales, US and overseas manufacturing plants, R&D and strategic planning. Mr Molloy has also exited a number of leading US medical devices firms, including publicly traded cerebral oxygenation monitoring firm, CAS Medical Inc., and Revolutionary Medical Devices. He also serves on the Board at Augustine Medical a privately held market leader in medical arena temperature management. He is a member of the Risk Management committee.
    Mr Stephen (Steve) Denaro Company Secretary
    Mr John Cox Chief Executive Officer Feb 2022
    John Cox Chief Executive Officer
    James Hunter Chief Financial Officer
    John Cox Chief Operating Officer
    Stephen (Steve) Denaro Company Secretary

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Thorney Investment Group 48,107,416 19.90%
    Christopher Patrick Hart <Chd Ip Account> 27,542,517 11.39%
    Bond Street Custodians Limited <Salter D79836 A/C> 10,000,000 4.14%
    J P Morgan Nominees Australia Pty Limited 5,525,000 2.29%
    Mr Neil Lawrence Anderson & Ms Genieve Kathryn Anderson <Anderson Family A/C> 5,348,477 2.21%
    Asia Union Investments Pty Ltd 4,607,306 1.91%
    Mr Melvyn John Bridges 4,552,392 1.88%
    Mobius Medical Investments Pty Ltd <Mobius Medical Inv Unit A/C> 3,752,164 1.55%
    Dixson Trust Pty Ltd 3,397,739 1.41%
    Mr Anthony John Huntley 2,750,000 1.14%
    New Highland Pty Ltd <King Family A/C> 2,171,208 0.90%
    Norfolk Blue Pty Ltd <Norfolk Blue A/C> 2,000,000 0.83%
    Ceralius Pty Ltd <Bridge A/C> 1,840,858 0.76%
    Picherit'S Farm Pty Ltd <Huntley Super Fund A/C> 1,750,000 0.72%
    Spg Trading Pty Ltd 1,670,765 0.69%
    Mr Michael Frank Manford <Atlo Super Fund A/C> 1,626,401 0.67%
    Bond Street Custodians Limited <Lam1 D08017 A/C> 1,604,174 0.66%
    Bond Street Custodians Limited <Rsalte D62375 A/C> 1,484,105 0.61%
    Pethol (Vic) Pty Ltd <Macdy No 5 Super Fund A/C> 1,461,379 0.60%
    Wellsey Pty Ltd 1,413,469 0.58%